Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) CEO Dr Seth Lederman tells Proactive the clinical-stage biopharmaceutical company has signed a second research collaboration agreement with Massachusetts General Hospital.
Dr Lederman says while the first collaboration is centered on heart transplantation, the second focuses on developing its antibody TNX-1500 to prevent and treat kidney transplant rejection.